Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solid matrix-antibody-antigen (SMAA) complexes for constructing multivalent subunit vaccines.

R E Randall

    Immunology Today
    |October 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Liquid-liquid phase inclusion bodies in acute and persistent parainfluenaza virus type 5 infections.

    The Journal of general virology·2024
    Same author

    Single-cell studies of IFN-β promoter activation by wild-type and NS1-defective influenza A viruses.

    The Journal of general virology·2016
    Same author

    Human IFIT1 Inhibits mRNA Translation of Rubulaviruses but Not Other Members of the Paramyxoviridae Family.

    Journal of virology·2016
    Same author

    Deep sequencing analysis of defective genomes of parainfluenza virus 5 and their role in interferon induction.

    Journal of virology·2013
    Same author

    ISG56/IFIT1 is primarily responsible for interferon-induced changes to patterns of parainfluenza virus type 5 transcription and protein synthesis.

    The Journal of general virology·2012
    Same author

    Activation of the beta interferon promoter by paramyxoviruses in the absence of virus protein synthesis.

    The Journal of general virology·2011
    Same journal

    Foreword.

    Immunology today·2020
    Same journal

    The origin and significance of anti-DNA antibodies.

    Immunology today·2014
    Same journal

    Mutations of class II MHC molecules.

    Immunology today·2014
    Same journal

    Antigen processing at the molecular level.

    Immunology today·2014
    Same journal

    Phenotypically and functionally distinct T-cell subsets in anti-tumor responses.

    Immunology today·2014
    Same journal

    Are MHC class II-restricted cytotoxic T lymphocytes important?

    Immunology today·2014
    See all related articles

    Developing multivalent vaccines requires multiple antigens. Solid matrix-antibody-antigen (SMAA) complexes offer a practical method for creating effective vaccines that induce both humoral and cell-mediated immunity.

    Area of Science:

    • Immunology
    • Vaccinology
    • Biotechnology

    Background:

    • Successful vaccination often necessitates inducing both humoral and cell-mediated immune responses.
    • This requires vaccines containing multiple antigens from a single infectious agent.

    Purpose of the Study:

    • To propose a practical and effective method for producing multivalent vaccines.
    • To discuss the advantages and future potential of solid matrix-antibody-antigen (SMAA) complexes.

    Main Methods:

    • Construction of solid matrix-antibody-antigen (SMAA) complexes.
    • Incorporation of multiple antigens from the same microbe into the vaccine.

    Main Results:

    • SMAA complexes present a viable strategy for multivalent vaccine development.

    Related Experiment Videos

  • This approach facilitates the induction of comprehensive immune responses.

    • Conclusions:

    • Solid matrix-antibody-antigen (SMAA) complexes are a promising platform for next-generation vaccines.
    • Further research into SMAA complexes could enhance vaccine efficacy against various diseases.